Analyst Consensus ?
ConsensusHold40 ratings
Bullish1947.5%
Neutral1537.5%
Bearish615.0%
1 unmapped firm rating excluded from the percentages.
AstraZeneca PLC · AZN · FY2026 Q1 · Calendar Q2 2026
AstraZeneca Q1 2026: Oncology Strength Offsets CVRM Headwinds
The quarter's reported growth and maintained full-year outlook support a constructive operating picture, but the durability of growth depends on pipeline execution and managing CVRM, pricing, and competitive pressures.
Reported Before market openNYSEHealthcare
$289.47B market cap
90quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$2.58
Consensus $2.57
EPS surprise
+0.4%
Reported versus consensus
Reported revenue
$15.29B
Consensus $14.93B
Revenue surprise
+2.4%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-0.8%
Event window
SPY move
-0.0%
Same window
Abnormal move
-0.8%
Stock minus SPY
Volume
2.3×
Versus trailing sessions
Subsequent drift
+0.1%
Up to 20 sessions
AZNSPY benchmark
Ask FN2 about AZN FY2026 Q1
Transcript, numbers and history already loaded
Why did AZN fall 0.8% after beating EPS estimates in FY2026 Q1?What changed in AZN's guidance and outlook in FY2026 Q1?Give me the bull and bear case for AZN after FY2026 Q1 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The supplied transcript analysis reports revenue growth of 8% year over year and operating-profit growth of 12%, with oncology and rare disease growth offsetting CVRM headwinds. The event scorecard shows EPS of 2.58 versus 2.57 estimated and revenue of 15.288 billion versus 14.93254 billion estimated. Full-year guidance was maintained.
Guidance delta
Maintained: the transcript analysis says management reaffirmed full-year revenue growth in the mid- to high-single digits and low-double-digit EPS growth.
Key takeaways
- Oncology and rare disease were identified as growth drivers, while CVRM remained a headwind.
- The event scorecard shows reported EPS and revenue modestly above estimates.
- Management maintained the full-year outlook described in the transcript analysis.
- Pipeline development and manufacturing capacity were emphasized as investment priorities.
Management priorities
- Advance pipeline programs and prepare launches identified in the call, including baxdrostat, camizestrant, and tozorakimab.
- Expand ADC manufacturing capacity in Singapore and Qingdao, and invest in pipeline development.
- Pursue broader COPD indications and multiple Phase III programs, as described in the transcript analysis.
Follow AZN with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$186.65Current
$156Low
$180Average
$216High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 1, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| UBS | Buy | Neutral | Upgrade | Feb 13, 2025 |
| Erste Group | Buy | Hold | Upgrade | Sep 11, 2024 |
| TD Cowen | Buy | Buy | Maintain | Aug 12, 2024 |
| Argus Research | Buy | Buy | Maintain | May 30, 2024 |
| BMO Capital | Outperform | Outperform | Maintain | Apr 26, 2024 |
| Deutsche Bank | Hold | Sell | Upgrade | Apr 16, 2024 |
| Jefferies | Hold | Buy | Downgrade | Jan 3, 2024 |
| SVB Leerink | Outperform | Outperform | Maintain | Nov 14, 2022 |
| DZ Bank | Hold | Sell | Upgrade | Feb 11, 2022 |
| Morgan Stanley | Overweight | Equal Weight | Upgrade | Dec 7, 2020 |
| Cowen & Co. | Outperform | Outperform | Maintain | Dec 2, 2019 |
| Investec | Hold | Buy | Downgrade | Nov 19, 2018 |
| Argus | Buy | Hold | Upgrade | May 5, 2018 |
| Leerink Swann | Market Perform | Market Perform | Maintain | Feb 6, 2018 |
| JP Morgan | Overweight | Neutral | Upgrade | Dec 29, 2017 |
| Bernstein | Outperform | Market Perform | Upgrade | Sep 22, 2017 |
| Liberum | Hold | Buy | Downgrade | Sep 14, 2017 |
| Credit Suisse | Neutral | Underperform | Upgrade | May 15, 2017 |
| Exane BNP Paribas | Neutral | Outperform | Downgrade | Sep 14, 2016 |
| Goldman Sachs | Sell | Neutral | Downgrade | Apr 11, 2016 |
| HBSC | Hold | Buy | Downgrade | Feb 8, 2016 |
| Oddo Securities | Neutral | Upgrade | Jan 26, 2016 | |
| Barclays | Equal Weight | Underweight | Upgrade | Jan 19, 2016 |
| HSBC | Buy | Hold | Upgrade | Sep 2, 2015 |
| Berenberg | Buy | Hold | Upgrade | Jul 2, 2015 |
| LBBW Research | Hold | Sell | Upgrade | May 19, 2015 |
| SEB Enskilda | Buy | Hold | Upgrade | Feb 3, 2015 |
| Danske Bank | Sell | Buy | Downgrade | May 5, 2014 |
| Panmure Gordon | Buy | Hold | Upgrade | Apr 29, 2014 |
| Panmure | Buy | Hold | Upgrade | Apr 29, 2014 |
| Societe Generale | Hold | Sell | Upgrade | Apr 28, 2014 |
| Kepler Cheuvreux | Hold | Reduce | Upgrade | Apr 28, 2014 |
| Citigroup | Buy | Neutral | Upgrade | Apr 22, 2014 |
| Bank of America | Underperform | Neutral | Downgrade | Mar 3, 2014 |
| B of A Securities | Underperform | Neutral | Downgrade | Mar 3, 2014 |
| Bryan Garnier | Neutral | Buy | Downgrade | Dec 20, 2013 |
| Nordea Equity | Buy | Sell | Upgrade | Sep 16, 2013 |
| Nordea | Buy | Sell | Upgrade | Sep 16, 2013 |
| Swedbank | Reduce | Sell | Maintain | Aug 2, 2013 |
| Natixis | Neutral | Reduce | Upgrade | Mar 22, 2013 |
| Pareto Securities | Sell | Hold | Downgrade | Oct 26, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $186.65. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| HSBC | Analyst unavailable | $216 | $179.64 | +15.7% | Dec 10, 2025 |
| Morgan Stanley | Analyst unavailable | $206 | $180.34 | +10.4% | Dec 3, 2025 |
| Berenberg Bank | Luisa Hector | $194 | $141.64 | +3.9% | Jul 9, 2025 |
| BMO Capital | Etzer Darout | $176 | $162.38 | -5.7% | Nov 13, 2024 |
| BMO Capital | Etzer Darout | $178 | $159.88 | -4.6% | Sep 11, 2024 |
| Argus Research | John Eade | $170 | $153.68 | -8.9% | May 30, 2024 |
| BMO Capital | Etzer Darout | $164 | $153.48 | -12.1% | May 28, 2024 |
| Leerink Partners | Andrew Berens | $158 | $129.72 | -15.3% | Jul 12, 2023 |
| BMO Capital | Analyst unavailable | $164 | $139 | -12.1% | Jan 5, 2023 |
| Leerink Partners | Analyst unavailable | $156 | $130.18 | -16.4% | Nov 11, 2022 |
| Leerink Partners | Analyst unavailable | $150 | $134.34 | -19.6% | May 4, 2022 |
Track every rating change on AZN the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationAstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris.…
Historical context
All AZN earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| BTSG BrightSpring Health Services, Inc. Common Stock | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +11.1% | BrightSpring posts strong Q3 growth while maintaining guidance |
| ABBV AbbVie Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.4% | +1.4% | AbbVie raises 2026 guidance as Skyrizi and Rinvoq drive Q3 growth |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +10.0% | BrightSpring posts strong Q3 growth as pharmacy leads |
| REGN Regeneron Pharmaceuticals, Inc. | FY2026 Q3 · Calendar Q4 2026 | +21.6% | +13.3% | Regeneron posts strong Q3 growth as pipeline expands |
| EXEL Exelixis, Inc. | FY2026 Q3 · Calendar Q4 2026 | +6.0% | +4.8% | Exelixis highlights zanzalintinib pipeline after strong Q3 |
| BBIO BridgeBio Pharma, Inc. | FY2026 Q3 · Calendar Q4 2026 | +22.5% | +6.0% | BridgeBio advances three launches while Attruby momentum holds |
Latest beats and misses
Who reports nextBeat on EPS
- CHDFY2026 Q3 · October 30, 2026+2.2% EPS+1.2% move
- AZNFY2026 Q3 · October 30, 2026+7.3% EPS+7.0% move
- FRTFY2026 Q3 · October 30, 2026+3.9% EPS-1.1% move
- CVXFY2026 Q3 · October 30, 2026+8.4% EPS+1.8% move
- BTSGFY2026 Q3 · October 30, 2026+14.2% EPS+11.1% move
- EXCFY2026 Q3 · October 30, 2026+10.4% EPS+0.5% move
Missed on EPS
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
- VALEFY2026 Q3 · October 29, 2026-24.6% EPS+1.9% move
- DLR-PLFY2026 Q3 · October 29, 2026-8.4% EPS— move
- DLR-PKFY2026 Q3 · October 29, 2026-8.4% EPS— move
Get the AZN recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-11-01T20:20:51.240119+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-01T20:20:51.237442+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-01. For educational purposes only; not investment advice.